AF
PLX icon

Allworth Financial’s Protalix BioTherapeutics PLX Stock Holding History

Allworth Financial’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$709 Buy
304
+278
+1,069% +$589 ﹤0.01% 4788
2026
Q1 		$57 Buy
+26
New +$65 ﹤0.01% 5057

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Allworth Financial's PLX Position: Q2 2026 in Review

Allworth Financial increased its Protalix BioTherapeutics (PLX) stake by 1,069% in Q2 2026, buying an estimated $589 and bringing the position to 304 shares worth $709. The position accounts for ﹤0.01% of the portfolio, ranked #4788.

Allworth Financial first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Allworth Financial held 304 shares of Protalix BioTherapeutics worth $709 as of Q2 2026.
  • Allworth Financial bought 278 Protalix BioTherapeutics shares in Q2 2026, an estimated $589.
  • Protalix BioTherapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4788 holding.
  • Allworth Financial first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.